Test Price
2,800 AED✅ Home Collection Available
DEAF1 Gene Genetic Test for Autosomal Dominant Intellectual Disability Type 24 (MRD24)
Executive Summary & Core Metrics
DNA Labs UAE offers the DEAF1 gene genetic test for diagnosing Autosomal Dominant Intellectual Disability Type 24 (MRD24) with 99.9% diagnostic accuracy. The test includes VIP mobile phlebotomy and temperature-controlled cold-chain home collection (available daily 8 AM–11 PM), free clinical geneticist tele-consultation, and direct insurance verification via WhatsApp at +971 54 548 8731. Our DHA-licensed facility (License 1143) ensures full compliance with UAE data protection and healthcare regulations.
Test Overview & Methodology
Comprehensive DEAF1 Gene Sequencing
DEAF1 gene sequencing identifies pathogenic variants causing autosomal dominant intellectual disability type 24 (MRD24). This next-generation sequencing (NGS) test detects single-nucleotide variants, small indels, and copy-number changes with superior analytical sensitivity—providing a definitive molecular diagnosis for affected children and at-risk family members.
| Feature | Our Test (DHA-Certified) | Closest Alternative (Conventional Assay) |
|---|---|---|
| Methodology | NGS with full gene coverage, copy-number variant analysis | Sanger sequencing of selected exons only |
| Diagnostic Sensitivity | 99.9% for all variant types | ~85% (misses deep intronic/CNV) |
| Turnaround Time | 3–4 Weeks with ISO Cold-Chain Home Collection | 6–8 Weeks, hospital-based sampling |
| Post-Test Support | Free Clinical Geneticist Tele-Consult & Pedigree Review | Standard report delivery |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403 notes: “A positive DEAF1 variant confirms the molecular etiology, enabling accurate recurrence-risk counseling and prenatal/preimplantation options. Nevertheless, variant interpretation requires clinical correlation with the child’s developmental phenotype. A negative result does not exclude other genetic or acquired causes—further evaluation by a pediatric neurologist remains essential.”
Advisory Notice
Medication Warning
Do not discontinue or modify any prescribed medication (e.g., antiepileptics, neuroleptics) without explicit consultation with your treating physician. Abrupt changes may precipitate severe decompensation.
Exclusion Criteria
- Acute febrile illness or active infection: postpone sample collection until fully recovered.
- Recent blood transfusion or hematopoietic stem-cell transplant within 4 weeks—may interfere with germline DNA analysis.
- Coagulopathy or severe thrombocytopenia: physician clearance required before venipuncture.
- ER Red Flags: New-onset seizures, acute encephalopathy, or loss of previously acquired skills—seek emergency care immediately; genetic testing is not a substitute for acute management.
Patient FAQ & Clinical Guidance
1. What does the DEAF1 genetic test detect, and how reliable is it?
This NGS reads the entire DEAF1 gene, achieving over 99.9% diagnostic sensitivity for single-nucleotide variants, small insertions/deletions, and copy-number changes—making it the most definitive non-invasive molecular assay available for MRD24.
2. How long do results take and what does the report include?
Results are ready in 3–4 weeks, and your report includes variant classification (ACMG criteria), zygosity, interpretation by a clinical geneticist, and tailored recommendations for genetic counseling and family management.
3. Is home sample collection safe and approved for children?
Absolutely; our pediatric-trained phlebotomists use distraction techniques and butterfly needles, fully complying with UAE health regulations for minors, and all samples are transported in validated temperature-controlled kits with 24/7 monitoring.
UAE Regulatory & Data Privacy Adherence
All services are delivered in strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | DEAF1 Gene Genetic Test for Autosomal Dominant Intellectual Disability Type 24 (MRD24) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or dried blood spot |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage and copy-number variant analysis |
| ICD-10-CM Code | Q87.8 |
| LOINC Code | 82107-4 |
| DHA Facility License & Laboratory Address | Licensed under DHA License No. 1143. Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians